Mingyu Cheng, M.D., Ph.D.
Assistant Clinical Professor
Mingyu Cheng is not currently accepting new patients. For assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
Additional Numbers
Phone
Philosophy of Care
Patient-centered care delivered with compassion and excellence.
Clinical Interests
Dr. Cheng's clinical interests include renal & transplant pathology, genitourinary (GU) pathology and head & neck pathology.
Research/Academic Interests
Dr. Cheng’s research focuses on:
- Pathogenesis and diagnostic criteria of light chain-associated acute tubulointerstitial nephritis (LC-ATIN).
- Dendritic cells in renal transplant rejection.
Division
Anatomic Pathology
Medical School
M.D., Hubei Medical University, Shiyan, Hubei, China 1995
Other School
Ph.D., Tsinghua University, Bejing, China 2004
Residency
Anatomic and Clinical Pathology, Louisiana State University Health Shreveport, Shreveport LA 2013-2017
Fellowship
Renal and Genitourinary Pathology, Louisiana State University Health Shreveport, Shreveport LA 2017-2018
Second Prize, 20th Annual Albert G. Smith Resident Research Symposium, Louisiana State University Health Science Center, Shreveport LA, 2018
Ghadially Award (formerly the Pathologist-in-Training Award), United States and Canadian Academy of Pathology (USCAP) Annual Meeting, Boston MA, 2015
Third Prize, 16th Annual Albert G. Smith Resident Research Symposium, Louisiana State University Health Science Center, Shreveport LA, 2014
Third Prize, Center for Integration of Medicine and Innovative Technologies (CIMIT) Conference, Boston MA, 2005
Jespersen Nizamic T, Huang Y, Alnimri M, Cheng M, Chen LX, Jen KY. COVID-19 Manifesting as Renal Allograft Dysfunction, Acute Pancreatitis, and Thrombotic Microangiopathy: A Case Report. Transplant Proc. 2021 May;53(4):1211-1214. doi:10.1016/j.transproceed.2020.10.048. Epub 2020 Dec 18. PMID:33436168.
Cheng M, Gu X, Turbat-Herrera EA, Herrera GA. Tubular Injury and Dendritic Cell Activation Are Integral Components of Light Chain-Associated Acute Tubulointerstitial Nephritis. Arch Pathol Lab Med. 2019 Oct;143(10):1212-1224. doi:10.5858/arpa.2018-0032-OA. Epub 2019 May 7. PMID:31063013.
Gu X, Cheng M, Herrera GA. Kidney carcinoid tumor: Histological, immunohistochemical and ultrastructural features. Ultrastruct Pathol. 2018 Jan-Feb;42(1):18-22. doi:10.1080/01913123.2017.1388321. Epub 2017 Dec 1. PMID:29192809.
Cheng M, Gu X, Herrera GA. Dendritic cells in renal biopsies of patients with acute tubulointerstitial nephritis. Hum Pathol. 2016 Aug;54:113-20. doi:10.1016/j.humpath.2016.03.020. Epub 2016 Apr 13. PMID:27085555.
Yoshida R, Cheng M, Murray MM. Increasing platelet concentration in platelet-rich plasma inhibits anterior cruciate ligament cell function in three-dimensional culture. J Orthop Res. 2014 Feb;32(2):291-5. doi:10.1002/jor.22493. Epub 2013 Oct 4. PMID:24122902.
Cheng M, Johnson VM, Murray MM. Effects of age and platelet-rich plasma on ACL cell viability and collagen gene expression. J Orthop Res. 2012 Jan;30(1):79-85. doi:10.1002/jor.21496. Epub 2011 Jul 11. PMID:21748791.
Cheng M, Wang H, Yoshida R, Murray MM. Platelets and plasma proteins are both required to stimulate collagen gene expression by anterior cruciate ligament cells in three-dimensional culture. Tissue Eng Part A. 2010 May;16(5):1479-89. doi:10.1089/ten.TEA.2009.0199. PMID:19958169.
Engelmayr GC Jr, Cheng M, Bettinger CJ, Borenstein JT, Langer R, Freed LE. Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater. 2008 Dec;7(12):1003-10. doi:10.1038/nmat2316. Epub 2008 Nov 2. PMID:18978786.
Cheng MY, Moretti M, Engelmayr CG, Nichol J, Freed EL. Insulin-like growth factor-I and slow, bi-directional perfusion enhance the formation of tissue-engineered cardiac grafts. Tissue Engineering. 2008 Aug 28;15(3):645-653. doi:10.1089/ten.tea.2008.0077.
Cheng MY, Park H, Moretti M, Engelmayr CG, Freed EL. Effects of regulatory factors on engineered cardiac tissue in vitro. Tissue Engineering. 2007 Dec;13(11):2709-2719. doi:10.1089/ten.2006.0414.